A drug from the sea that strikes tumor-associated macrophages

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Allavena, Paola ^a   Germano, Giovanni ^a   Belgiovine, Cristina ^a   D'Incalci, Maurizio ^b   Mantovani, Alberto ^a,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiogenesis; Chemotherapy; Marine drug; Micro environment; Tumor associated macrophages

Indexed keywords

CASPASE 8; MACROPHAGE DERIVED CHEMOKINE; TRABECTEDIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VASCULOTROPIN;

ADOPTIVE TRANSFER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SELECTION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; EVIDENCE BASED MEDICINE; HUMAN; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84884915030     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24614     Document Type: Article

References (10)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/nature07205
2. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362:875-85; PMID:20220182; http://dx.doi. org/10.1056/NEJMoa0905680
3. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j. cell.2010.03.014
4. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; PMID:22039576; http://dx.doi. org/10.1158/2159-8274.CD-10-0028
5. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122:787-95; PMID:22378047; http://dx.doi.org/10.1172/JCI59643
6. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23:277-86; PMID:23518347; http://dx.doi. org/10.1016/j.ccr.2013.02.013
7. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9:2157-63; PMID:20647340; http://dx.doi.org/10.1158/1535-7163.MCT-10-0263
8. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, et al. Efficacy of trabectedin (ecteinascidin- 743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8:595-602; PMID:17586092; http://dx.doi.org/10.1016/S1470-2045(07)70175-4
9. Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, et al. A retrospective analysis of antitumour activity with trabectedin in translocationrelated sarcomas. Eur J Cancer 2012; 48:3036-44; PMID:22749255; http://dx.doi.org/10.1016/j. ejca.2012.05.012
10. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013; 23:249-62; PMID:23410977; http://dx.doi. org/10.1016/j.ccr.2013.01.008